Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Lantheus in a research note issued on Tuesday, February 18th. Leerink Partnrs analyst R. Ruiz forecasts that the ...
The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback